 Systematic review on effectiveness radiotherapy in adults with drug resistant NNFE  Evidence is based on case series, randomized trials are lacking  Future: Is fractionated radiotherapy able to reduce long-term toxicity?
Organization has estimated that more than 50 million patients suffer from epilepsy worldwide. [1] [2] [3] According to the International League Against Epilepsy several types of epilepsy exist 4, 5 .
In this review we focus on non-neoplastic focal epileptic lesions (NNFE), associated with focal seizures, which have a localized, well-circumscribed network of discharges. 6 Non-neoplastic lesions, that have been described by the European Epilepsy Brain Bank consortium as the pathological substrate of focal seizures include, in descending order of frequency, hippocampal sclerosis (36.4%), long-term epilepsy-associated tumors (23.6%), malformations of cortical development (19.8%), vascular malformations (6.1%) and glial scars (4.8%) as well as no lesion (7.7%). 7 The most frequent nonneoplastic lesions of drug-resistant focal epilepsies, constituting about 80% of all resective epilepsy surgery cases, are hippocampal sclerosis and malformations of cortical development besides long-term epilepsy-associated tumors. 7 In the group of low-grade epilepsy associated tumors, some of these tumors can, although very rare, dedifferentiate into high-grade neoplastic subforms. 8, 9, 10 This is one reason why we focus on hippocampal sclerosis and malformations of cortical development in this review. A second reason is that almost all well-documented clinical series of focal epilepsy and radiosurgery include patients with tumors. Since the beginning of the 21st century, studies are emerging describing non-space-occupying lesions, mainly hippocampal sclerosis, with long-term follow-up. 11, 12, 13, 14, 15 Only very recently, studies on the radiosurgical treatment of periventricular heterotopias and focal cortical dysplasias have been published, although with a short follow-up period of the treated patients. 16, 17 The type and origin of epilepsy determines the prognosis and the efficacy of the treatment. Currently, the two most frequently used therapeutic options include antiepileptic drug (AED) therapy and resective epilepsy surgery. Still resective epilepsy surgery is underused globally and patients tend to be referred with a long delay. 18, 19 Noteworthy, postoperative seizure free outcome varies between 60-90% depending, among others, on the pathological substrate. 20 The third, less frequently used therapeutic option is radiation therapy (RT). This noninvasive approach may be superior to surgery when the epileptogenic region is located near the eloquent cortex or deeply sited brain areas. In theory, RT may achieve a better neurotransmitter equilibrium than resective epilepsy surgery, and thus result in better neuropsychological outcome despite the late response effects. 20, 21 Stereotactic RT (SRT) is a high-precision three-dimensional external beam radiation therapy technique directing
beams to a well-defined target, relying on detailed imaging and precise treatment set-up to deliver the radiation dose while sparing the surrounding normal tissue. By using multiple fractions (so-called fractionated) SRT, the dose is delivered in multiple sessions over a longer period of time, instead of a single-session large dose, also referred to as stereotactic radiosurgery (SRS). Fractionated SRT has been proven to be superior to SRS when considering tolerance dose of normal brain tissue and cranial nerves and thus higher (radio-)biologically equivalent doses can safely be delivered using the former. 22 Since long-term side effects of RT may comprise the induction of secondary tumors and growth delay in children, we focused on adult patients in this review. So far, several publications have underlined the potential value of RT in patients with drug-resistant epilepsy. 18, 19, 20, 23 To date, however, no systematic review has been published on the efficacy of RT in adults patients with drug-resistant FNNE, excluding bias effects of previous resection. Therefore, this systematic review summarizes the available evidence for efficacy (no or rare seizures in Engel class I&II patients 24 ) and treatment-related side effects in patients with focal drug-resistant epilepsy undergoing RT.
Materials and Methods

Research protocol
To develop the research protocol and identify the scope of the review, we followed a structured approach to identify the patient population, interventions, comparators, outcomes, and study design (PICOS criteria). 25 As ILAE-terminology on epilepsy recently changed (Fisher 2017) , search terms for epilepsy were "focal" and "localization related".
The research question was defined as: what is the level of evidence on the efficacy of primary RT for drug-resistant FNNE in adults? For this, therapeutic benefit was defined as seizure frequency reduction using the modestly adapted Engel classification. We adapted only the Engel class III, which was defined as an improvement of epilepsy frequency with more than 75% (Figure 1 ). Therapy-induced complications were defined as late radiation damage. The research protocol contained a comprehensive search strategy and screening criteria for abstracts, titles and full text articles.
Eligibility criteria, search strategy and study selection
A comprehensive search was performed to identify the current papers in PubMed (National Center for Biotechnology Information, NCBI), Ovid Medline, Cochrane library, Embase and Web of Science. PubMed was used as the primary data source; Ovid Medline, Cochrane library, Embase and Web of Science were used to extract additionally available articles (supplementary Table I and II). These search strategies were frequently performed with the last search in May, 2017. To finalize the systematic literature search all included articles' reference lists were crossed-checked (citation tracking) on potential
relevant studies that met the inclusion criteria.
After literature collection, completed abstracts and titles were first assessed on identical records and duplicate findings were removed from the search. In addition, identical patient cohorts were only entered once, comprising the study with most information on patient characteristics, seizure outcome and the longest follow-up period. Abstracts and full text articles were assessed using inclusion criteria and exclusion criteria (supplementary Table III ). Two investigators (EP and DE) established the research protocol and independently performed the literature searches. A third independent reviewer (ET) was consulted if no agreement was reached amongst the two investigators.
Data collection
Data collection was performed with the use of a well-defined questionnaire in Microsoft Excel (supplementary Table IV ). Unfortunately, we were unable to perform a metaanalysis for controls since studies were not designed with control groups.
Data quality assessment and risk of bias within studies
To assess the methodological quality of the included studies the QUADAS-2 checklist was intended to be used. 24 However, most domains (patient selection, index test, reference standard and flow and timing) of the QUADAS checklist were not applicable to our research. 24 Mainly the index test, which in our study would have been a control group, was not described in the studies included in this review. Therefore, it was decided to use a modified version of the QUADAS checklist to assess the risk of bias and applicability to the research question of all included articles. In this way the individual quality of each included study was evaluated (supplementary Table V) . For all studies information on inand exclusion criteria, loss to follow-up, follow-up time, definition of outcome measure and exposure to radiotherapy was scored.
Dose-response model
Dose response was tested with Kendall's tau correlation 17 . The biological effective dose (BED) is commonly used for isoeffective dose calculations when comparing differing fractionation schedules, i.e. fraction dose and number of fractions. After converting the physical dose to BED using an α/β of 10 Gy (BED10), a logistic probability density function (logit model) was fitted by the least-square method:
where D = BED10, D50 is the BED10 at 50% response, and γ50 is the normalized slope at D50. The 95% confidence intervals (95% CI) were determined by bootstrapping.
Results
Data extraction and bias assessment
Study selection
The study selection process complying with the PRISMA statement 25 is illustrated in Figure 2 . Sixteen out of 170 initially identified studies were included in this systematic literature study (n=170 patients).
Risk of bias within studies
A summary of the parameters that we used to identify the risk of bias is found in supplementary Table IV . Nine out of 16 studies explicitly described inclusion criteria that were carefully selected and enabled comparisons between study populations. However, exclusion criteria were not well defined in most publications and by comparing the seizure frequency before and after therapy, the patient was used as his/her own control.
None of the studies used control groups. Therefore, selection bias could not be identified.
In addition, information on the cohorts from which the study populations were drawn was not given, which hampered comparisons. A final risk of bias was the fact that the definitions of the post-treatment seizure outcome measures were not in accordance with the Engel classification in seven of the included studies, but sufficient information was provided to enable the transformation to the radiotherapy-adapted Engel class (RAEC).
RAEC I was defined as seizure free, II as rarely seizures, III as an improvement of more than 75% and class IV as no significant improvement (see Figure I ).
Patient selection in individual studies
The most important information from each included study is presented as a framework for conclusions. In the study by Régis et al. 11 , patient number 11 and 18 were identical to the patients in the study by Rheims et al. 26 . For reason of longer follow-up, these patients were analyzed in the latter study only. In addition, two patients discussed in the study by Usami et al. 27 were identical to patients in the article of Kawai et al. 28 . Since more details about the patient characteristics were available in the article of Kawai et al. 28 these two patients were analyzed there. In the studies by Kawamura et al. 29 , Usami et al. 27 , Barbaro et al. 12 , Regis et al.
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, Srikijvilaikul et al. 30 , and Rheims et al. 26 some patients underwent surgery or died before the end of the follow-up time. Since only Srikijavilaikul et al. 30 documented in detail which specific patients underwent surgery or died, these patients could not be excluded from the systematic review in the other studies. Therefore, the effect of RT on the outcome of seizures could not be undoubtedly shown in these three included studies, posing a possible bias in treatment outcome. Table 1 shows the RT parameters of the included studies. Detailed information on the study characteristics is shown in Table 2 . Long-term toxicity is summarized in Table 3 . Noteworthy, the number of patients questioned regarding their subjective radiationinduced side effects is unknown for they were objectively visualized by magnetic resonance imaging.
Data analysis
Study characteristics
Radiation therapy dose schedules and prescription
The included studies used a wide range of dose schedules, from single fractions prescribing 13-25 Gy as marginal dose to 2, 7, 12 and 15 fractions of 6, 3, 4, 2.5, 3 and 2 Gy, respectively, prescribed to the 95% isodose ( Table 1 ). The maximum dose in the target volume was only reported in the study of Rauch et al.
31
Treatment effect on seizure outcome
As measure of efficacy of RT, the RAEC system was used in this systematic review. Most studies (n=9) used the Engel classification system, five studies did not use any of the classification systems but provided sufficient information on seizure outcome, and two studies indicated the seizure outcome with ILAE classification. To be able to compare study outcome, the investigators independently assessed these seven studies and transformed the seizure outcome to RAEC (Figure 1) . 16, [26] [27] [28] [30] [31] [32] [33] RAEC I and II were subsequently combined since these classes are both assumed to give a beneficial effect after treatment (class I no seizures; class II rare seizures; Figure 1 ) 24 . Twelve of the 16 studies reported a positive effect of RT on the seizure outcome defined by the total percentage of RAEC I and II patients, ranging from 25%-95% per study, with an overall average of 57% (98 patients). In the two smallest studies (two and three patients, respectively), RT had no favorable effect on the seizure outcome (class IV), although treatment was delivered with similar techniques, dose per fraction and target volumes compared to the other studies. The fitted dose-response graph is illustrated in Figure 3 . As can be gathered from the graph, a BED10 of 69−80 Gy is required for an RAEC I+II response in 50−75% of the patients. Furthermore, this figure suggests that higher response rates can be obtained at a lower BED10 for multi-fraction schemes than for single-fraction schemes.
Long-term toxicity
MRI changes
All studies reported on long-term toxicity after treatment with RT, of which 10 studies included imaging information on structural/anatomical MRI ( Table 3 ). The first changes on MRI scans were observed after 6 months whereas they also occurred 10 years following RT. 28 Hyperintense regions on the T2-weighted MRI scans were first detected after 6 months (peak 9-24 months) and tended to disappear after a few years, whereas four studies described cystic lesions several years after treatment which needed resection. [11] [12] [13] [14] 27, 29, 30, 32, 34, 35 Surgical intervention Overall, 20% (34 patients; range 7-100%) of the patients in nine of the 16 studies underwent subsequent surgery. [12] [13] [14] 26, 27, 29, 28, 32, 34, 35 In six of these studies resection was performed because of persisting seizures, mostly within a 2 years follow up period, in those patients in whom AEDs could not control the epilepsy. 26, 28, 29, 32, 34, 36 In all studies, in which MRI was performed, the symptoms that were described by the patient were corresponding to an alteration visible on MRI scans. In three studies treating with SRS (21, 23 and 25 Gy), radionecrosis was reported to have occurred requiring subsequent surgery 7-12 years following treatment. 13, 27, 29 In one study, one patient underwent surgery without any abnormalities seen on MRI. 12 Noteworthy, following fractionated treatment schedules, no patient required surgical resection or developed radionecrosis.
Neurocognitive functioning
Some of the studies reported on cognitive functions. Grabenbauer et al. 32 treated nine patients with temporal lobe epilepsy and found post-treatment memory deficit in 2/9 (22%) and verbal deficit in 3/9 (33%) patients. In the second study from Rauch et al. 31 , verbal decline was found in 45% of the treated patients for temporal lobe epilepsy and extratemporal lobe epilepsy. Quigg et al. 37 published the neuropsychological outcome of the article by Barbaro et al. 12 , in which they concluded that there was no difference from baseline regarding language, verbal memory, cognitive efficiency and mental flexibility, nor mood. Conversely, QOL scores improved at 24 and 36 months, with those patients attaining seizure remission by month 24 accounting for the majority of the improvement.
Regis et al.
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observed no neuropsychological deterioration 2 years after treatment, reporting the quality of life being significantly better than that before surgery. Vojtěch et al. 36 published their neuropsychological results in a separate article in 2015, in which they reported no significant changes in memory or intelligence at two years after radiosurgery 38 . The effect on daily functioning has not been stated. As Taphoorn et al. 39 A C C E P T E D M A N U S C R I P T described, AED itself are more strongly associated with cognitive deficits than RT.
Miscellaneous side-effects
Headache, nausea and/or vomiting related to increased intracranial pressure and edema on MRI, were reported in 12/16 studies and easily treated with corticosteroids. The moment of onset and duration of these complaints was not described in detail. [11] [12] [13] 26, 27, 29, 31, [32] [33] [34] [35] [36] Visual field deficits, i.e., quadrantanopia and hemianopia, were reported in 6/16 studies with an incidence of 14-59%. [11] [12] [13] [14] 33, 36 Strikingly, quadrantanopia was also found in the study of Liang et al. 33 after administration of 2 fractions of 6 Gy, a total dose not generally considered to cause visual deficits.
Discussion
The optimum treatment for mesial temporal lobe epilepsy would be eliminating seizures with low risk, yet sparing the hippocampal function and surrounding brain. When no neoplastic lesion is present it was hypothesized by Régis et al. 23 that single fraction stereotactic radiation therapy is inducing changes in the functioning of the neural tissue, by inducing remodeling of the glial environment, and is leading to the modulation of function while preserving basic processing. Chang et al. 15 proposed progression of vascular injury and tissue necrosis following radiotherapy to be associated with a remission of seizures. Barbaro et al. 12 randomized patients by dose; they demonstrated that the higher dose arm had better outcomes (within statistical power limits). This same effect was found in other small series underlining the tendency of higher doses to have a better antiepileptic effect than lower doses [40] [41] [42] [43] . Maesawa et al. 44 showed in a rat model, that SRS controlled epilepsy accompanied by stabilization of memory compared with untreated epileptic rats without causing subsequent behavioral impairment, for high (60 Gy) as well as low dose (30 Gy), supporting the hypothesis that even this relatively lower dose RT could be effective. The lowest listed radiosurgical single dose is 13 Gy as a marginal dose (see Fig. 1 ).
Also outside of the mesial temporal structures, crucial for a successful seizure outcome after resective epilepsy surgery or SRS is to define and precisely delineate the seizure onset zone (SOZ) or the so-called focal epileptic generator. There is a worldwide growing tendency to consider the potential epileptogenic network as important as the focal lesion on MRI. As clearly illustrated by Ladino et al. 45 and Stefan et al. 46 , heterotopia associated seizures can arise from the heterotopia alone (= focus) but can also be generated from overlying and surrounding cortex, another distant heterotopic nodule or even a dual pathology lesion, like hippocampal sclerosis (= network theory). Before definitive treatment, open resection or SRS, is advised to the patient strong evidence must be A C C E P T E D M A N U S C R I P T collected whether the MRI focus or the network generates the seizures in this particular patient, e.g. by invasive electrode implantation.
Summary of evidence
This systematic review gives an overview of the available literature on the efficacy of primary RT for FNNE in adults. Due to the lack of case-control studies, the results of this study only provide level 4 evidence indicating that RT may be a therapeutic option to reduce the seizure frequency for NNFE in adults. 47 When considering the low level of evidence there is an inevitable ceiling effect because the absence of "control" groups is nearly inherent in surgical studies since the demands of equipoise would not allow design of studies with a non-treatment arm in most US and European studies. For example the study of Wiebe et al. 48 randomizing open surgery to a wait-list, could not be performed in the US, and concerns over sudden unexpected death in epilepsy (SUDEP) in control arms prevents any non-treatment/wait-list designs.
In most of the studies it was not described whether AED treatment was reduced or discontinued and in those reporting on it, AED intake remained identical as prior to RT.
Only two studies showed no improvement of seizure control after RT. 28, 30 A reason for this may be that RT is able to reduce the seizure frequency, but a vast number of the reported patients were not completely seizure free after RT thus requesting surgery.
Furthermore, the long-term toxicity (e.g., cystic lesions) of RT may be another reason for the high rate of surgical interventions after primary RT. Interestingly, two studies investigated the cost effectiveness and found that surgery and Gamma Knife for hippocampal sclerosis were both safe and effective, but the surgical resection led to better results in freedom of epilepsy, (93% versus 54%) and a reduction of cost. 49, 50 Limitations of the study Our study has some limitations. First of all, the only randomized study was retrievable in abstract-form only and attempts receiving a manuscript in preparation from the authors failed. Consequently, the work has not been peer-reviewed and thereupon modified yet, which hampers the resulting strength of our work. Although we checked in detail with available data, there is always the potential of patient overlap to occur between multicenter studies. In addition, control groups were not reported in the majority of studies, thereby limiting the strength of the study's design. Furthermore, studies described the primary outcome parameter differently using ILAE and pure description versus the Engel classification. Therefore the two reviewers (EP and DE) translated the seizure outcome of the corresponding studies to the RAEC to be able to compare the seizures, based on earlier clarification of terms used to name seizures. 6 For this review, we assumed that the new term "focal epilepsy" is equivalent to the former term "localization related epilepsy".
Moreover, only 1 out of 16 studies reported information on the patient's quality of life. It is important that future research will include quality of life questionnaires in the design.
Seizure outcome and long-term toxicity should be weighed against quality of life. In addition, two studies did not define their follow-up time. Nevertheless, we have decided to include these studies since important information about the efficacy of RT in epileptic patients was described. 27, 28 No conclusions can be drawn on the effect of fractionation compared to single-fraction on treatment outcome and toxicity due to limited amount of available fractionated studies.
In our dose response analyses we assumed the Linear-Quadratic (LQ) model to be correct in determining the 2Gy-per-fraction equivalent dose (BED10) for fraction doses up to 24 Gy. Brown et al. 51 concludes that the LQ model is reasonably predictive of in vitro and in vivo normal tissue dose response relations in the dose per fraction range of 1.8 to 20 Gy and that it is currently not possible to identify an alternative high-dose model that performs better than the LQ for predicting cell killing. Even the lowest dose schedule showed a moderate result defined as Engel class I-III of 57%. 33 Side-effects were similar in this study except for cyst formation, which was not seen. In order to derive a possible future fractionation schedule, we derived a dose-effect relationship, however, the definition of the (correct) target volume based on reported outcome (epilepsy frequency) is mandatory though still lacking. We agree with Régis et al. 52 suggesting that further basic research is needed for better understanding the influence of dose, volume, target topography and dose distribution homogeneity on the molecular effect in treating epilepsy. In addition, some recent studies hypothesize that the effect of RT should not be qualified as a destruction of the glial environment but as a modulation of the neural tissue. In particular in FNNE, this would be of interest. 12, 20, 23 
Radiobiology
The majority of treatments for epilepsy have been with SRS due to technical factors, mainly related to the requirements for immobilization of the patient's head and the availability of targeting systems. Although SRS has been shown to reduce seizure frequency in various forms of epilepsies, its mechanism of action remains unclear.
Different mechanisms have been postulated as the basis of an anti-epileptic effect of SRS, such as the destruction of the epileptic focus and its pathways of spread by A C C E P T E D M A N U S C R I P T necrotizing SRS doses, or suppression of the epileptic activity as a neuromodulation effect at non-necrotizing doses. 53, 54 There is no knowledge about fractionation effects for control of non-lesional epilepsy. From a radiobiological point of view, it is not clear whether SRS can better achieve the therapeutic goal than fractionated SRT with lower doses per fraction. Traditionally, the therapeutic effect of SRS is to destroy a small volume of brain tissue by radionecrosis, which results from vascular endothelial cell damage causing occlusion of small arterial vessels. There is growing interest that the same therapeutic effect may also be achieved by lower, fractionated doses of radiation, not inducing necrosis but having a neuromodulatory effect with possibly the same therapeutic and less unwanted effects. Studies are underway to investigate the threshold doses to achieve such neuromodulation. 53, 55 Since there are no conclusive data on the value of the α/β of epileptogenic lesions, we assumed the α/β to be the same as for proliferating tissue like in brain metastasis or tumor tissue. It remains unknown whether the use of the α/β value of non-neoplastic tissue or even normal brain tissue would be more adequate. Although changing the value of α/β will change the absolute BED values, it hardly changes the relative positions of the data points in the dose response curve.
Furthermore, this does not change the conclusion that the response correlates with BED.
However, the difference in BED between single and multi-fraction schedules will increase: an α/β of 2.2 Gy instead of 10 Gy will cause a shift of the data points from the singlefraction schedules further to the right in relation to the multi-fraction schedules. This suggests the response is sensitive to fractionation, and a fractionated scheme would be favorable over a single-fraction scheme.
Suggestions for future research
This systematic review gives rise to the following suggestions for future research on RT for FNNE. First, more information on the quality of life of epileptic patients is compulsory (with information about AED reduction after treatment). Although seizures are not completely controlled after treatment, patients may benefit from seizure reduction, which is sometimes already a relief. Second, neurocognitive testing should be standard in studies on seizure frequency to gain knowledge on the effect of RT on the neurocognitive functioning. Thirdly, the definition of the (correct) target volume based on reported outcome (epilepsy frequency) is mandatory though still lacking. Functional MRI may augment defining this target volume. Fourth, little information is known about LINACbased fractionated (stereotactic) radiotherapy and only four out of 16 studies that were included in this review used this technique. Hence, the effect of fractionation could not be assessed in detail. Therefore, the next step in assessing radiotherapy for FNNE is to improve the therapeutic ratio by reducing toxicity, which currently has a high incidence and is often the cause of resection after several years of follow-up. Bearing in mind the A C C E P T E D M A N U S C R I P T superior normal-tissue tolerance when employing a fractionated SRT scheme, future clinical trials may for example use 32−38 fractions of 1.8 Gy to obtain such response frequencies. The radiation techniques currently available allow for accurate dose delivery to a small volume of brain tissue. The first step to improve the therapeutic ratio would be to use lower total doses to similar volumes (e.g., by fractionation) in order to avoid healthy tissue destruction under iso-effect conditions. Once such doses have been shown to be equally effective, the radiosurgical use of charged particle beams with protons or carbon ions may further enhance the therapeutic ratio, based on their lower integral dose, lower risk of side effects and enhanced biological effectiveness. [54] [55] [56] After improvement of the therapeutic ratio, prospective randomized-controlled trials to define the value of radiotherapy compared to anti-epileptic drugs, surgery, and other invasive approaches are urgently required.
Conclusions
Radiotherapy is a possible treatment option for focal epilepsy even though its present role in the management of drug-resistant epilepsy is limited. So far, no valid studies have been published to assess the efficacy of radiotherapy for drug-resistant FNNE in adults with a sufficiently high level of evidence. Since randomized control studies are lacking, existing evidence is mainly limited to case series. Hence, there is an urgent need for prospective randomized-controlled trials to define its value compared to anti-epileptic drugs, surgery, and other invasive approaches. Further research is needed to establish agreement on target volume definition and to determine the optimal dose prescription in order to improve the current results of radiotherapy.
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